AI assistant
Candel Therapeutics, Inc. — Director's Dealing 2021
Jul 27, 2021
33336_dirs_2021-07-26_49c66326-0cea-4ffe-b0d0-574f9337f344.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-26
Reporting Person: Martell Christopher (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.55 | 2030-12-29 | Common Stock (16274) | Direct | |
| Stock Option (Right to Buy) | $6.64 | 2031-06-23 | Common Stock (16274) | Direct | |
| Series B Preferred Stock | $6.81 | Common Stock (283514) | Indirect | ||
| Warrants to purchase Common Stock | $6.81 | 2025-11-13 | Common Stock (283514) | Indirect |
Footnotes
F1: This option is fully vested and exercisable as of the date hereof.
F2: The Series B Preferred Stock has no expiration date.
F3: Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
F4: Warrants held by GTAM1 2012 Trust, for which the Reporting Person serves as trustee but is not a beneficiary. The Reporting Person disclaims beneficial ownership of these warrants except to the extent of his pecuniary interest therein, if any.